<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="116058">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01994668</url>
  </required_header>
  <id_info>
    <org_study_id>B3541001</org_study_id>
    <nct_id>NCT01994668</nct_id>
  </id_info>
  <brief_title>Phase 1 Study to Characterize the Safety and Pharmacokinetics of Single Intravenous Dose of Lorazepam in Healthy Japanese Adult Subjects</brief_title>
  <official_title>A Phase 1, Randomized Single-blind (Subject-blind), Placebo Controlled Study to Characterize the Safety and Pharmacokinetics of Single Intravenous Dose of Lorazepam in Healthy Japanese Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of 2-mg
      lorazepam intravenous administration in healthy Japanese adult subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs).</measure>
    <time_frame>Day 1 to  Day 4</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Relatedness to [study drug] was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the Concentration-Time Curve (AUC)</measure>
    <time_frame>Day1 to Day 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Lorazepam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorazepam</intervention_name>
    <description>A single intravenous administration of 2 mg lorazepam over 1 minute</description>
    <arm_group_label>Lorazepam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A single intravenous administration of 0.9% saline over 1 minute</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Japanese male and/or female subjects of non-childbearing potential.

          -  Body Mass Index of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg.

        Exclusion Criteria:

          -  History of sensitivity to lorazepam or other benzodiazepines.

          -  Evidence or history of acute narrow-angle glaucoma or sleep apnea syndrome.

          -  Significant psychiatric disorder, recurrent episodes of severe depression, or
             subjects with serious suicidal risk.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hachioji-shi</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3541001&amp;StudyName=Phase%201%20Study%20to%20Characterize%20the%20Safety%20and%20Pharmacokinetics%20of%20Single%20Intravenous%20Dose%20of%20Lorazepam%20in%20Healthy%20Japanese%20Adult%20Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 28, 2014</lastchanged_date>
  <firstreceived_date>November 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lorazepam</keyword>
  <keyword>intravenous</keyword>
  <keyword>pharmacolinetics</keyword>
  <keyword>healthy</keyword>
  <keyword>Japanese</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lorazepam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
